Last reviewed · How we verify
CPL500036 - low dose
CPL500036 is a low-dose drug with an unknown existing mechanism.
At a glance
| Generic name | CPL500036 - low dose |
|---|---|
| Sponsor | Celon Pharma SA |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, there is limited information available about the mechanism of action of CPL500036.
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia (PHASE2)
- Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |